|
|
|
Dynavax Reports Feedback From FDA Meeting Regarding HEPLISAV(TM) Biologic License Application Jun 10, 2013 Dynavax Reports First Quarter 2013 Financial Results May 6, 2013 Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors
Dynavax Appoints
David Novack as Senior Vice President, Operations and Quality Dynavax Reports Fourth Quarter and Year End 2012 Financial Results March 1, 2013
February 26, 2013 Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference December 17, 2012 Dynavax Announces FDA Advisory Committee Meeting Outcome for HEPLISAV(TM) November 15, 2012 Dynavax Reports Third Quarter 2012 Financial Results November 1, 2012 Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma October 31, 2012 |
Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
 |
